ACR: Age at Psoriasis Onset Sets Course for Psoriatic Arthritis

TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractPurpose of ReviewThe therapeutic response to biologic agents in psoriasis is significantly higher than observed in psoriatic arthritis (PsA). In this review, specific actions to improve treatment outcomes in PsA are discussed.Recent FindingsIncreased understanding of disease pathogenesis derived from improved preclinical models and advances in cell-based and molecular technologies provide new tools to identify therapeutic targets. In addition to the important contributions of metabolic comorbidities, chronic pain and the lack of a diagnostic biomarker signal the need for new strategies to improve outcomes. Potentia...
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research
Authors: Carli L, Calabresi E, Governato G, Braun J Abstract Spondyloarthritis (SpA) is the umbrella term for a broad spectrum of inflammatory rheumatic diseases with typical but also rather different clinical manifestations, limited laboratory abnormalities and characteristic imaging features. For classification purposes, a so-called non-radiographic form (nr-axSpA) is differentiated from a radiographic one (r-axSpA) which is almost identical to the classical ankylosing spondylitis (AS) that is genetically strongly associated with the major histocompatibility complex class 1 antigen HLA-B27. In axSpA, the axial sk...
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders. Here, the elucidation of key pathogenic factors such as IL-17A/IL-23 on the one hand and IL-4/IL-13 on the other hand profoundly changed our therapeutic practice. The knowledge on intracellular pathways and governing factors is shifting our attention to new druggable molecules. Multiple cytokine receptors signal through Janus kinases (JAKs) and associated signal transducer and activato...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: DMARDs & Immunosuppressives Drug Updates 2019 ACR/ARP Annual Meeting Psoriasis psoriatic arthritis tildrakizumab Source Type: research
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2)
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
The objective of this study was to evaluate the effectiveness and safety of ixekizumab in a cohort of psoriatic and psoriatic arthritis patients.MethodsWe conducted a retrospective study involving 201 patients affected by moderate-to-severe psoriasis and treated with ixekizumab at seven Italian University centers. Data analysis focused on 110 patients who started ixekizumab at baseline and completed at least 24  weeks of treatment.ResultsSignificant reduction of mean ( ± standard deviation) baseline Psoriasis Area Severity Index (PASI) score (14.3 ± 5.8) was detected at 4 weeks ...
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research
Conclusions: The remarkable differences among the few available data on the association between GSTM1/GSTT1 polymorphisms and psoriasis suggest the need for further studies, on different and larger populations, to improve knowledge on the pathogenesis of psoriasis and possibly provide more precise and personalized prevention and treatment in the future. PMID: 31774007 [PubMed - as supplied by publisher]
Source: Free Radical Research - Category: Research Tags: Free Radic Res Source Type: research
ConclusionIn a Taiwanese setting, no link between psoriasis or psoriatic arthritis and suicidal behavior was detected.
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research
Authors: Mysliwiec H, Harasim-Symbor E, Baran A, Szterling-Jaworowska M, Milewska AJ, Chabowski A, Flisiak I Abstract Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with higher risk of cardiovascular events and metabolic syndrome than psoriasis without arthritis. Fatty acids (FA) play an important role as signaling molecules in inflammatory and metabolic pathways. The aim of the study was to evaluate serum FA concentration in patients with PsA and to investigate the correlations of FA with the clinical and biochemical markers. Material and methods: We measured 14 FA serum c...
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
CONCLUSION: Secukinumab treatment does not affect the humoral response to influenza vaccine of patients with PsA. PMID: 31767465 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
More News: Arthritis | Pharmaceuticals | Psoriasis | Psoriatic Arthritis | Rheumatology | Study